Flexion’s Pandemic Rebound: How Zilretta Dropped 80% But Is Still Coming Out Ahead

The knee osteoarthritis injection was hit hard by COVID-19 restrictions, at first. But CEO Mike Clayman reflected in an interview about how the pandemic experience is helping fuel further growth for Zilretta.   

Knee joint
• Source: Shutterstock

Physician-administered drugs were one of the categories most affected by the pandemic, as patients postponed office visits and delayed treatment where possible. That’s how things started out for Flexion Therapeutics, Inc. and its intra-articular injection for osteoarthritis of the knee, Zilretta, but the company’s quick reaction to the new circumstances actually led it to significantly grow its business. 

Zilretta’s Commercial Performance

Zilretta had been on a steady upward trajectory since launching at the end of 2017, and the COVID-19 pandemic coincided with a promotional push – spending that Flexion attempted to claw back as the pandemic depressed sales. (See charts below.)

Selling expenses dropped from $96.3m for 2019 to $72.3m for 2020, largely from “the elimination of live presence at industry conferences, reduction in in-person physician speaker programs and reductions in select marketing programs and materials, as well as a reduction in travel expenses due to physician office limitations and travel guidelines and restrictions at the state and local level.” Flexion also temporarily paused Zilretta manufacturing to avoid excess inventory, and recommenced production at the end of 2020.

But despite a rough year, total 2020 sales rose to $85.6m, up 17% from 2019. “Considering the unprecedented challenges we experienced last year due to the pandemic, we are very pleased with these results,” Clayman told the firm’s full-year 2020 earnings call on 10 March. “The pandemic had a tremendous impact on patient flows to doctors' offices and corresponding demand for Zilretta in late Q1 and Q2. However, we saw sales recover nicely throughout the second half.”

The firm ended 2020 with slightly more than 2% penetration of the intra-articular injection market, which it sees as just scratching the surface, especially as it plans to expand to frontline use for knee OA.

First quarter 2021 sales were $24.6m. “We were really pleased with the quarter. There were a couple of expected pushes and pulls on it. And a couple of potentially unexpected pushes and pulls on it,” Clayman told the 12 May Q1 earnings call.

The first quarter usually sees about a 10% drop for knee OA injections, driven by insurance deductibles resetting and winter weather – which was exacerbated this year by the atypical severe weather across parts of the US with extended power outages that resulted in delayed office procedures, the CEO explained. Zilretta sales were also impacted by the rollout of the COVID vaccines, particularly in Zilretta’s target age population.

“Out of an abundance of caution, some physicians opted to defer IA steroid injections for a period of two weeks prior to COVID vaccination through two weeks post completion of the vaccination regimen,” Clayman noted. Flexion believes these deferrals are largely past, barring a resurgence of COVID-19. It expects patient flow to office to remain at 80% through mid-year, “with some incremental improvement” in the second half of 2021.

As a sign of its confidence there will be continued momentum in sales, the firm issued its first guidance for Zilretta sales, projecting $120m-$130m for the full year.

The guidance “seems reasonable as momentum appears to be building,” BMO Capital Markets analyst Gary Nachman said in a 13 April note. BMO is bullish on the market opportunity for Zilretta, forecasting peak sales of about $650m based on “positive feedback from physician consultants, and also potential upside from shoulder OA. There are barriers to entry given challenges in formulating [long-acting] steroid[s] and patents to 2031,” the analyst added, and expansions to Flexion’s “pipeline is adding more shots on goal and represents optionality.”

Guggenheim analyst Dana Flanders was similarly optimistic in a 13 May note: “We continue to like the setup for FLXN as Zilretta is poised for further growth, and with the positive FX201 data presented at ASGCT and enrollment progress on FX301, we believe 2021 could be an important year for FLXN’s pipeline.”

The company ended Q1 with $154m in cash and equivalents, which should cover the company through the middle of 2020, but when pushed on a 13 April pre-Q1 call outgoing chief financial officer David Arkowitz said the company would remain opportunistic regarding fundraising.

In year three of a steadily growing launch, Zilretta combines the short-acting corticosteroid triamcinolone acetonide with a poly lactic-co-glycolic acid...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

Scrip-NewProducts (Premium-2): Top 12 Pharma Companies: Pfizer Tops The Leaderboard Again

 
• By 

The world’s biggest pharmaceutical companies mostly saw growth in 2024 but 2025 promises to be more of a mixed bag with headwinds including losses of exclusivity, Medicare Part D redesign and challenges in the Chinese market.

Innovent/GenFleet Score China’s First KRAS G12C Inhibitor Approval

 

The nod will help unlock a national market for the partners’ Dupert (fulzerasib) in which roughly 50,000 people are expected to be newly diagnosed with lung cancer harboring the KRAS G12C mutation in 2025. Meanwhile, two other homegrown rivals are also closing in on marketing clearances in China.

Cagrisema Leads The Charge For 2025

 

2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.  

Small But Mitey: Tarsus To Amp Up Strong Xdemvy Launch

 

Tarsus Pharmaceuticals is putting more sales and marketing heft behind its novel eyelid disease therapy, Xdemvy, to capitalize on a solid start in a previously untapped market.    

More from Scrip

Test

Sponsored by :

Clinical Trial Complexity Is Reshaping Evidence Collection Clinical trial innovation has historical

As clinical trials grow more complex, execution pressures are changing where and how evidence is collected.

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.